Stay updated with breaking news from Erosense. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of IceCure Medical Ltd (ICCM) are up 77% on Tuesday following the release of an independent study titled "Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors" in Cancers.
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that in parallel with the growing adoption of ProSense®, the number of independent, non-sponsored studies of its cryoablation system has significantly increased. In addition to the 12 studies already published in peer reviewed journals and presented in scienti
Blade Surface Aerodynamic Pressure Measurements Both the aerodynamic/acoustic design of the rotor blades and their performance during operation can be improved by measuring the aerodynamic surface pressure distribution. For blade design, an